Directed new share issue in Nordic Nanovector ASA (NO) — NOK 250 million

Carnegie acted as joint bookrunner in the directed new share issue of 17,857,143 new shares at a subscription price of NOK 14 per share. Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in the development of CD37-targeted therapies for haematological cancers and immune diseases.
January 2022.